Cost-effectiveness of detemir-based basal/bolus therapy versus NPH-based basal/bolus therapy for type 1 diabetes in a UK setting: an economic analysis based on meta-analysis results of four clinical trials

References

• UKPDS Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837–53
   PubMed Web of Science ®Google Scholar
• UKPDS Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854–65
   PubMed Web of Science ®Google Scholar
• The DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977–86
   PubMed Web of Science ®Google Scholar
• Palmer AJ, Weiss C, Sendi PP, Neeser K, Brandt A, Singh G, et al. The cost-effectiveness of different management strategies for type I diabetes: a Swiss perspective. Diabetologia 2000;43:13–26
   PubMed Web of Science ®Google Scholar
• Palmer AJ, Sendi PP, Spinas GA. Applying some UK Prospective Diabetes Study results to Switzerland: The cost-effectiveness of intensive glycemic control with metformin versus conventional control in overweight patients with type 2 diabetes. Schweiz Med Wochenschr 2000;130: 1034–40
   Google Scholar
• Gray A, Raikou M, McGuire A, Fenn P, Stevens R, Cull C, et al. Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41). United Kingdom Prospective Diabetes Study Group. Br Med J 2000;320:1373–8
   PubMed Web of Science ®Google Scholar
• Epidemiology of severe hypoglycemia in the diabetes control and complications trial. The DCCT Research Group. Am J Med 1991;90:450–9
   PubMed Web of Science ®Google Scholar
• Weight gain associated with intensive therapy in the diabetes control and complications trial. The DCCT Research Group. Diabetes Care 1988;11:567–73
   PubMedGoogle Scholar
• Purnell JQ, Hokanson JE, Marcovina SM, Steffes MW, Cleary PA, Brunzell JD. Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. Diabetes Control and Complications Trial. JAMA 1998;280:140–6
   Google Scholar
• A desktop guide to Type 1 (insulin-dependent) diabetes mellitus. European Diabetes Policy Group 1998. Diabet Med 1999;16: 253–66
   Google Scholar
• NICE. National Institute for Clinical Excellence. Technology appraisal guidance – No. 53. Guidance on the use of long-acting insulin analogues for the treatment of diabetes – insulin glargine. 12–1–2002
   Google Scholar
• Zhao HX, Stenhouse E, Soper C, Hughes P, Sanderson E, Baumer JH, et al. Incidence of childhood-onset Type 1 diabetes mellitus in Devon and Cornwall, England, 1975–1996. Diabet Med 1999;16:1030–5
   PubMed Web of Science ®Google Scholar
• Staines A, Bodansky HJ, Lilley HE, Stephenson C, McNally RJ, Cartwright RA. The epidemiology of diabetes mellitus in the United Kingdom: the Yorkshire Regional Childhood Diabetes Register. Diabetologia 1993;36:1282–7
   PubMed Web of Science ®Google Scholar
• Raymond NT, Jones JR, Swift PG, Davies MJ, Lawrence G, McNally PG, et al. Comparative incidence of Type I diabetes in children aged under 15 years from South Asian and White or Other ethnic backgrounds in Leicestershire, UK, 1989 to 1998. Diabetologia 2001;44\(Suppl. 3):B32–6
   Google Scholar
• Feltbower RG, McKinney PA, Parslow RC, Stephenson CR, Bodansky HJ. Type 1 diabetes in Yorkshire, UK: time trends in 0–14 and 15–29-year-olds, age at onset and age-period-cohort modelling. Diabet Med 2003;20: 437–41
   Google Scholar
• Harvey JN, Craney L, Kelly D. Estimation of the prevalence of diagnosed diabetes from primary care and secondary care source data: comparison of record linkage with capture-recapture analysis. J Epidemiol Community Health 2002;56:18–23
   Google Scholar
• Palmer AJ, Roze S, Valentine WJ, Minshall M, Foos V, Lurati F, et al. The CORE Diabetes Model: projecting long term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision making. Curr Med Res Opin 2004;20\(Suppl. 1):S5–26
   Google Scholar
• Palmer AJ, Roze S, Valentine WJ, Minshall M, Foos V, Lurati F, et al. Validation of the CORE Diabetes Model against epidemiological and clinical studies. Curr Med Res Opin 2004;20\(Suppl. 1):S27–40
   Google Scholar
• Hermansen K, Fontaine P, Kukolja KK, Peterkova V, Leth G, Gall MA. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with Type 1 diabetes. Diabetologia 2004;47:622–9
   PubMed Web of Science ®Google Scholar
• Clarke P, Gray A, Legood R, Briggs A, Holman R. The impact of diabetes-related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65). Diabet Med 2003;20: 442–50
   Google Scholar
• Department of Health. NHS Reference Costs 2003 and National Tariff 2004. http://www.dh.gov.uk/PublicationsAndStatistics/ P u b l i c a t i o n s / P u b l i c a t i o n s P o l i c y A n d G u i d a n c e / PublicationsPolicyAndGuidanceArticle/fs/en?CONTENT_ ID=4070195&chk=UzhHA3. [Accessed 30 April 2004]
   Google Scholar
• Netten A, Curtis L. Unit Costs of Health and Social Care 2003. http://www.pssru.ac.uk/pdf/uc2003/uc2003_inflation.pdf. [Acessed 1 Sept 2004]
   Google Scholar
• Clarke P, Gray A, Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making 2002;22: 340–9
   Google Scholar
• Mathers C, Vos T, Stevenson C. Burden of disease and injury in Australia. Bruce, ACT: Australian Institute of Health and Welfare, 1999
   Google Scholar
• Tengs TO, Wallace A. One thousand health-related quality-of-life estimates. Med Care 2000;38:583–637
   PubMed Web of Science ®Google Scholar
• NICE website: http://www.nice.org.uk/Docref.asp?d=93882. [Accessed June 2004]
   Google Scholar
• Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ 2004;13:437–52
   PubMed Web of Science ®Google Scholar
• The DCCT Research Group. The absence of a glycemic threshold for the development of long-term complications. The perspective of the Diabetes Control and Complications Trial. Diabetes 1996;45:1289–98
   PubMed Web of Science ®Google Scholar
• The DCCT Research Group. Resource utilization and costs of care in the Diabetes Control and Complications Trial. Diabetes Care 1995;18:1468–78
   PubMed Web of Science ®Google Scholar
• Home P, Bartley P, Russell-Jones D, Hanaire-Broutin H, Heeg JE, Abrams P, et al. Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial. Diabetes Care 2004;27: 1081–7
   Google Scholar
• Stevens RJ, Kothari V, Adler AI, Stratton IM. The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clin Sci (Lond) 2001;101:671–9
   PubMed Web of Science ®Google Scholar
• Kothari V, Stevens RJ, Adler AI, Stratton IM, Manley SE, Neil HA, et al. UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine. Stroke 2002;33:1776–81
   PubMed Web of Science ®Google Scholar
• Murabito JM, D’Agostino RB, Silbershatz H, Wilson WF. Intermittent claudication. A risk profile from The Framingham Heart Study. Circulation 1997;96:44–9
   PubMed Web of Science ®Google Scholar
• D’Agostino RB, Russell MW, Huse DM, Ellison RC, Silbershatz H, Wilson PW, et al. Primary and subsequent coronary risk appraisal: new results from the Framingham study. Am Heart J 2000;139:272–81
   Google Scholar
• Kannel WB, D’Agostino RB, Silbershatz H, Belanger AJ, Wilson PW, Levy D. Profile for estimating risk of heart failure. Arch Intern Med 1999;159:1197–1204
   PubMed Web of Science ®Google Scholar
• Laing SP, Swerdlow AJ, Slater SD, Burden AC, Morris A, Waugh NR, et al. Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes. Diabetologia 2003; 46:760–5
   PubMed Web of Science ®Google Scholar
• Roper NA, Bilous RW, Kelly WF, Unwin NC, Connolly VM. Excess mortality in a population with diabetes and the impact of material deprivation: longitudinal, population based study. Br Med J 2001;322:1389–93
   Google Scholar
• Marks JB, Raskin P. Cardiovascular risk in diabetes: a brief review. J Diabetes Complications 2000;14:108–15
   PubMed Web of Science ®Google Scholar
• Lehto S, Ronnemaa T, Pyorala K, Laakso M. Poor glycemic control predicts coronary heart disease events in patients with type 1 diabetes without nephropathy. Arterioscler Thromb Vasc Biol 1999;19:1014–9
   PubMed Web of Science ®Google Scholar
• Tuomilehto J, Borch-Johnsen K, Molarius A, Forsen T, Rastenyte D, Sarti C, et al. Incidence of cardiovascular disease in Type 1 (insulin-dependent) diabetic subjects with and without diabetic nephropathy in Finland. Diabetologia 1998;41:784–90
   PubMed Web of Science ®Google Scholar
• Lepore M, Pampanelli S, Fanelli C, Porcellati F, Bartocci L, Di Vincenzo A, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000;49:2142–8
   Google Scholar
• Heise T, Nosek L, Ronn BB, Endahl L, Heinemann L, Kapitza C, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 2004;53:1614–20
   PubMed Web of Science ®Google Scholar
• Raskin P, Guthrie RA, Leiter L, Riis A, Jovanovic L. Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes. Diabetes Care 2000;23: 583–8
   Google Scholar
• Pieber TR, Plank J, Goerzer E. Duration of action, pharmaco-dynamic profile and between-subject variability of insulin detemir in subjects with type 1 diabetes. Diabetes 2004;51\(Suppl. 2):A53
   Google Scholar
• Pieber TR, Grill V, Kristensen A, Draeger E. Timing of dose-administration of insulin detemir is flexible and results in lower and less variable glucose levels and less weight gain than NPH insulin. Diabet Med. In press
   Google Scholar
• Russell-Jones D, Simpson R, Hylleberg B, Draeger E, Bolinder J. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen. Clin Ther 2004;26:724–36
   Google Scholar
• Harvey JN, Rizvi K, Craney L, Messenger J, Shah R, Meadows PA. Population-based survey and analysis of trends in the prevalence of diabetic nephropathy in Type 1 diabetes. Diabet Med 2001;18:998–1002
   PubMed Web of Science ®Google Scholar
• Younis N, Broadbent DM, Harding SP, Vora JR. Prevalence of diabetic eye disease in patients entering a systematic primary care-based eye screening programme. Diabet Med 2002;19:1014–21
   PubMed Web of Science ®Google Scholar
• Jonsson B, Hansson L, Stalhammar NO. Health economics in the Hypertension Optimal Treatment (HOT) study: costs and cost-effectiveness of intensive blood pressure lowering and low-dose aspirin in patients with hypertension. J Intern Med 2003;253:472–80
   Google Scholar
• Benett IJ, Lambert C, Hinds G, Kirton C. Emerging standards for diabetes care from a city-wide primary care audit. Diabet Med 1994;11:489–92
   PubMed Web of Science ®Google Scholar
• Currie CJ, Morgan CL, Peters JR. The epidemiology and cost of inpatient care for peripheral vascular disease, infection, neur-opathy, and ulceration in diabetes. Diabetes Care 1998;21:42–8
   Google Scholar
• United Kingdom Prospective Diabetes Study Group. Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. Br Med J 1998;317:720–6
   PubMed Web of Science ®Google Scholar
• NHS UK Transplant December 2002
   Google Scholar
• Ghatnekar O, Persson U, Willis M, Odegaard K. Cost effectiveness of Becaplermin in the treatment of diabetic foot ulcers in four European countries. Pharmacoeconomics 2001;19:767–78
   PubMed Web of Science ®Google Scholar
• James M, Turner DA, Broadbent DM, Vora J, Harding SP. Cost effectiveness analysis of screening for sight threatening diabetic eye disease. Br Med J 2000;320:1627–31
   Google Scholar
• OMNILABS (UK) Limited, Price List, effective October 2000, London. 2000
   Google Scholar
• Scuffham P, Carr L. The cost-effectiveness of continuous sub-cutaneous insulin infusion compared with multiple daily injections for the management of diabetes. Diabet Med 2003;20:586–93
   PubMed Web of Science ®Google Scholar